ReviewMicrobiology (Reading, England)2009
Strategies for acquiring the phospholipid metabolite inositol in pathogenic bacteria, fungi and protozoa: making it and taking it.
Review in Microbiology (Reading, England), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 90 citations in OpenAlex.
- A culturomics approach reveals cross-feeding capacity of intestinal pig bacteria upon release of inositol from phytate.Microbiome · 2026Article
- Microbial Evolution and Systematics: Archaea and Bacteria.Progress in molecular and subcellular biology · 2026Review
- Efficacy of genetically modified Mycoplasma hyopneumoniae strains and their effect on local and cell-mediated immune responses in pigs.Veterinary research · 2025Article
- Comprehensive lipidomic analysis of the genusmSphere · 2024Article
- Article
- Efficient Production of Glucaric Acid by Engineered Saccharomyces cerevisiae.Applied and environmental microbiology · 2023Article
- Metabolomic profiling of bacterial biofilm: trends, challenges, and an emerging antibiofilm target.World journal of microbiology & biotechnology · 2023Review
- Azido Inositol Probes Enable Metabolic Labeling of Inositol-Containing Glycans and Reveal an Inositol Importer in Mycobacteria.ACS chemical biology · 2023Article
- Untargeted metabolomics to evaluate antifungal mechanism: a study of Cophinforma mamane and Candida albicans interaction.Natural products and bioprospecting · 2023Article
- Amine-Regulated pri-SMTP Oxidation in SMTP Biosynthesis inJournal of fungi (Basel, Switzerland) · 2022Article
- Genome Analyses of Two Blueberry Pathogens:Journal of fungi (Basel, Switzerland) · 2022Article
- Genome Features ofGenes · 2021Article
- Structural, Functional, and Metabolic Alterations in Human Cerebrovascular Endothelial Cells duringMicroorganisms · 2020Article
- Effects of exogenous glucose on Pseudomonas aeruginosa biofilm formation and antibiotic resistance.MicrobiologyOpen · 2019Article
- Quantitative Proteomic Analyses of a Pathogenic Strain and Its Highly Passaged Attenuated Strain ofBioMed research international · 2019Article
- The small RNA RssR regulates myo-inositol degradation by Salmonella enterica.Scientific reports · 2018Article
- Tamoxifen inhibits the biosynthesis of inositolphosphorylceramide in Leishmania.International journal for parasitology. Drugs and drug resistance · 2018Article
- Role of the inositol pyrophosphate multikinase Kcs1 in Cryptococcus inositol metabolism.Fungal genetics and biology : FG & B · 2018Article
- Article
- Insights on the virulence of swine respiratory tract mycoplasmas through genome-scale metabolic modeling.BMC genomics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
myo-Inositol (inositol) is an essential nutrient that is used for building phosphatidylinositol and its derivatives in eukaryotes and even in some eubacteria such as the mycobacteria. As a consequence, fungal, protozoan and mycobacterial pathogens must be able to acquire inositol in order to proliferate and cause infection in their hosts. There are two primary mechanisms for acquiring inositol. One is to synthesize inositol from glucose 6-phosphate using two sequentially acting enzymes: inositol-3-phosphate synthase (Ino1p) converts glucose 6-phosphate to inositol 3-phosphate, and then inositol monophosphatase (IMPase) dephosphorylates inositol 3-phosphate to generate inositol. The other mechanism is to import inositol from the environment via inositol transporters. Inositol is readily abundant in the bloodstream of mammalian hosts, providing a source from which many pathogens could potentially import inositol. However, despite this abundance of inositol in the host, some pathogens such as the bacterium Mycobacterium tuberculosis and the protist parasite Trypanosoma brucei must be able to make inositol de novo in order to cause disease (M. tuberculosis) or even grow (T. brucei). Other pathogens such as the fungus Candida albicans are equally adept at causing disease by importing inositol or by making it de novo. The role of inositol acquisition in the biology and pathogenesis of the parasite Leishmania and the fungus Cryptococcus are being explored as well. The specific strategies used by these pathogens to acquire inositol while in the host are discussed in relation to each pathogen's unique metabolic requirements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.